贝伐珠单抗联合卡铂紫杉醇化疗对Ⅲ B~Ⅳ期卵巢癌患者免疫功能及无进展生存期的影响

Effect of bevacizumab combined with"carboplatin+paclitaxel"chemotherapy on immune function and progression free survival in patients with stageⅢB-Ⅳovarian cancer

目的 探究贝伐珠单抗联合卡铂紫杉醇化疗对Ⅲ B~Ⅳ期卵巢癌患者免疫功能及无进展生存期(PFS)的影响。方法 本研究为一项回顾性研究,以2020年1月至2022年10月于上海交通大学医学院附属瑞金医院确诊为ⅢB~Ⅳ期的卵巢癌65例患者作为研究对象,根据治疗方法不同分为研究组(n=33)和对照组(n=32)。两组患者均行手术治疗,对照组术后采用“卡铂+紫杉醇”化疗,研究组在对照组治疗方法的基础上加用贝伐珠单抗,比较两组治疗效果。结果 两组总有效率、6个月生存率、12个月生存率和不良反应发生率差异均无统计学意义(均P>0.05)。与治疗前相比,两组患者经过治疗后,其血清糖类抗原125(CA125)、血清癌胚抗原(CEA)、CD4^(+)和CD4^(+)/CD8^(+)水平均下降(均P<0.05),且研究组CA125、CEA、CD4^(+)和CD4^(+)/CD8^(+)水平均低于对照组[(56.44±6.94) U·L^(-1) vs (87.19±7.36) U·L^(-1),(6.94±1.36) ng·m L^(-1) vs (10.91±1.84) ng·m L^(-1),(30.13±3.57)%vs (32.26±4.71)%,(0.85±0.19) vs (0.96±0.17)](t=17.335,9.914,2.059,2.457,均P<0.05);研究组CD8^(+)高于对照组[(35.45±3.39)%vs (33.60±3.51)%,t=16.832,P<0.05]。研究组PFS明显长于对照组[(5.41±1.63)个月vs (3.86±1.39)个月,t=4.119,P<0.05]。结论 贝伐珠单抗联合一线化疗能提高ⅢB~Ⅳ期卵巢癌患者疗效,改善免疫功能,延长PFS。

Objective To investigate the effect of bevacizumab combined with"carboplatin^(+)paclitaxel"chemotherapy on immune function and progression free survival(PFS)in patients with stageⅢB-Ⅳovarian cancer.Methods The clinical data of 65 patients who were diagnosed as suffering from stageⅢB-Ⅳovarian cancer in Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from January 2020 to October 2022 were retrospectively analyzed.They were divided into the study group(n=33)and control group(n=32)according to different treatment methods.All the 65 patients received surgical treatment.After surgery,the patients in the control group underwent"carboplatin^(+)paclitaxel"chemotherapy after surgery while those in the study group received bevacizumab based on the treatment regimen of the control group.The clinical efficacy was compared between the two groups.Results The differences of the total effective rate,6-month survival rate,12-month survival rate and incidence of adverse reactions were not statistically significant between the two groups(all P>0.05).Compared with those before treatment,the levels of serum carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA),CD4^(+)and CD4^(+)/CD8^(+)in both groups were decreased after treatment(all P<0.05).The levels of CA125,CEA,CD4^(+),and CD4^(+)/CD8^(+)in the study group were lower than those in the control((56.44±6.94)U·L^(-1) vs(87.19±7.36)U·L^(-1),(6.94±1.36)ng·mL^(-1) vs(10.91±1.84)ng·mL^(-1),(30.13±3.57)%vs(32.26±4.71)%,(0.85±0.19)vs(0.96±0.17))(t=17.335,9.914,2.059,2.457,all P<0.05),while the CD8^(+)levels in the study group was higher than that in the control((35.45±3.39)%vs(33.60±3.51)%,t=16.832,P<0.05).The PFS of the study group was significantly longer than that of the control((5.41±1.63)months vs(3.86±1.39)months,t=4.119,P<0.05).Conclusion The application of bevacizumab combined with"carboplatin^(+)paclitaxel"chemotherapy in patients with stageⅢB-Ⅳovarian cancer can effectively improve immune function,promote the efficacy and prolong PFS.